AU2005200716B2 - Method for producing L-glutamic acid by fermentation accompanied by precipitation - Google Patents
Method for producing L-glutamic acid by fermentation accompanied by precipitation Download PDFInfo
- Publication number
- AU2005200716B2 AU2005200716B2 AU2005200716A AU2005200716A AU2005200716B2 AU 2005200716 B2 AU2005200716 B2 AU 2005200716B2 AU 2005200716 A AU2005200716 A AU 2005200716A AU 2005200716 A AU2005200716 A AU 2005200716A AU 2005200716 B2 AU2005200716 B2 AU 2005200716B2
- Authority
- AU
- Australia
- Prior art keywords
- glutamic acid
- microorganism
- strain
- gene
- carbon source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title claims description 374
- 229960002989 glutamic acid Drugs 0.000 title claims description 188
- 238000004519 manufacturing process Methods 0.000 title claims description 24
- 238000000855 fermentation Methods 0.000 title claims description 20
- 230000004151 fermentation Effects 0.000 title claims description 20
- 238000001556 precipitation Methods 0.000 title description 6
- 244000005700 microbiome Species 0.000 claims description 95
- 238000000034 method Methods 0.000 claims description 56
- 241000588912 Pantoea agglomerans Species 0.000 claims description 50
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 36
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 32
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- 230000002950 deficient Effects 0.000 claims description 21
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 claims description 16
- 230000002378 acidificating effect Effects 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 241000588914 Enterobacter Species 0.000 claims description 11
- 239000011345 viscous material Substances 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 230000001376 precipitating effect Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 108010030844 2-methylcitrate synthase Proteins 0.000 claims description 6
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 claims description 6
- 108010071536 Citrate (Si)-synthase Proteins 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 102000006732 Citrate synthase Human genes 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 102000016901 Glutamate dehydrogenase Human genes 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 2
- 235000015250 liver sausages Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 39
- 239000013612 plasmid Substances 0.000 description 36
- 101150106096 gltA gene Proteins 0.000 description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 27
- 239000008103 glucose Substances 0.000 description 27
- 101150099894 GDHA gene Proteins 0.000 description 26
- 239000013078 crystal Substances 0.000 description 26
- 101150023641 ppc gene Proteins 0.000 description 22
- 241000588724 Escherichia coli Species 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 13
- 239000013611 chromosomal DNA Substances 0.000 description 13
- NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 13
- 101150111745 sucA gene Proteins 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 101100453819 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) kgd gene Proteins 0.000 description 10
- 229940041514 candida albicans extract Drugs 0.000 description 10
- 239000012138 yeast extract Substances 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 9
- 229960005091 chloramphenicol Drugs 0.000 description 9
- 241000186226 Corynebacterium glutamicum Species 0.000 description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 8
- 239000004327 boric acid Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 7
- 229930195722 L-methionine Natural products 0.000 description 7
- 239000004098 Tetracycline Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 7
- 229960002180 tetracycline Drugs 0.000 description 7
- 229930101283 tetracycline Natural products 0.000 description 7
- 235000019364 tetracycline Nutrition 0.000 description 7
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 7
- 150000003522 tetracyclines Chemical class 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241000186216 Corynebacterium Species 0.000 description 6
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108020005091 Replication Origin Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 108091006629 SLC13A2 Proteins 0.000 description 4
- 241000607720 Serratia Species 0.000 description 4
- 230000001851 biosynthetic effect Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 241000186146 Brevibacterium Species 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 241000588698 Erwinia Species 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 241000520272 Pantoea Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 108010000700 Acetolactate synthase Proteins 0.000 description 2
- 108010009924 Aconitate hydratase Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 101150108347 sdhB gene Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 101150055132 sucB gene Proteins 0.000 description 2
- 229960005137 succinic acid Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010092060 Acetate kinase Proteins 0.000 description 1
- 102000009836 Aconitate hydratase Human genes 0.000 description 1
- 241001147780 Alicyclobacillus Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 241001244729 Apalis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 101100134884 Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025) aceF gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101150090997 DLAT gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 101710098087 Gamma-aminobutyraldehyde dehydrogenase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 108020000311 Glutamate Synthase Proteins 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010048581 Lysine decarboxylase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108700023175 Phosphate acetyltransferases Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102000011929 Succinate-CoA Ligases Human genes 0.000 description 1
- 108010075728 Succinate-CoA Ligases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 238000009651 Voges-Proskauer test Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 108010008221 formate C-acetyltransferase Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 101150078036 odhB gene Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 101150024698 ppcA gene Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 101150117385 sucC gene Proteins 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant: AJINOMOTO CO., INC.
Invention Title: METHOD FOR PRODUCING L-GLUTAMIC ACID BY FERMENTATION ACCOMPANIED BY PRECIPITATION The following statement is a full description of this invention, including the best method of performing it known to me/us: TITLE OF THE INVENTION METHOD FOR PRODUCING L-GLUTAMIC ACID BY FERMENTATION ACCOMPANIED BY PRECIPITATION The entire disclosure in the complete specification of our Australian Patent Application No.
53452/00 is by this cross-reference incorporated into the present specification.
BACKGROUND OF THE INVENTION The present invention relates to a method for producing L-glutamic acid by fermentation accompanied by precipitation. L-Glutamic acid is widely used as a material in seasonings and so forth.
L-Glutamic acid is mainly produced by fermentative methods using so-called coryneform bacteria producing L-glutamic acid and belonging to the genus Brevibacterium, Corynebacterium or Micobacterium, or mutant strains thereof (Amino Acid Fermentation, pp.195-215, Gakkai Shuppan Center, 1986). As methods for producing L-glutamic acid by fermentation by using other bacterial strains, methods are known of using a microorganism belonging to the genus Bacillus, Streptomyces, Penicillium or the like Patent No.
3,220,929), a microorganism belonging to the genus Pseudomonas, Arthrobacter, Serratia, Candida or the like Patent No. 3,563,857), a microorganism belonging to the genus Bacillus, Pseudomonas, Serratia, Aerobacter aerogenes (currently referred to as Enterobacter aerogenes) or the like (Japanese Patent Publication (Kokoku) No. 32-9393), a mutant strain of Escherichia coli (Japanese Patent Application Laid-open (Kokai) No. 244970) and so forth. In addition, the inventors of the present invention have proposed a method H:\rochb\Keep\P55841.doc 17/02/05 for producing L-glutamic acid by using a microorganism belonging to the genus Klebsiella, Erwinia or Pantoea (Japanese Patent Application Laid-open No. 2000-106869).
Further, there have been disclosed various techniques for improving L-glutamic acid-producing ability by enhancing activities of L-glutamic acid biosynthetic enzymes through use of recombinant DNA techniques. For example, it has been reported that introduction of a gene coding for citrate synthase derived from Escherichia coli or Corynebacterium glutamicum was effective for enhancement of L-glutamic acid-producing ability in Corynebacterium or Brevibacterium bacteria (Japanese Patent Publication No. 7-121228). In addition, Japanese Patent Application Laid-open No. 61- 268185 discloses a cell harboring recombinant DNA containing a glutamate dehydrogenase gene derived from Corynebacterium bacteria. Further, Japanese Patent Application Laid-open No. 63-214189 discloses a technique for improving L-glutamic acid-producing ability by amplifying a glutamate dehydrogenase gene, an isocitrate dehydrogenase gene, an aconitate hydratase gene and a citrate synthase gene.
Although L-glutamic acid productivity has been considerably increased by breeding of the aforementioned microorganisms or improvement of production methods, development of methods for more efficiently producing Lglutamic acid at a lower cost is required to respond to further increase of the demand in future.
There is known a method wherein fermentation is performed with crystallizing L-amino acid accumulated in culture (Japanese Patent Application Laid-open No. 62-288).
In this method, the L-amino acid concentration in the culture is maintained below a certain level by precipitating the accumulated L-amino acid in the culture. Specifically, L-tryptophan, L-tyrosine or L-leucine is precipitated during fermentation by adjusting temperature and pH of the culture or adding a surface active agent to the medium.
While a fermentative method with precipitating L-amino acid is known as described above, amino acids suitable for this method are those of relatively low water solubility, and no example of applying the method to highly water-soluble amino acids such as L-glutamic acid is known. In addition, the medium must have low pH to precipitate L-glutamic acid.
However, L-glutamic acid-producing bacteria such as those mentioned above cannot grow under acidic conditions, and therefore L-glutamic acid fermentation is performed under neutral conditions Patent Nos. 3,220,929 and 3,032,474; Chao K.C. Foster J. Bacteriol., 77, pp.715-725 (1959)). Thus, production of L-glutamic acid by fermentation accompanied by precipitation is not known.
Furthermore, it is known that growth of most acidophile bacteria is inhibited by organic acids such as acetic acid, lactic acid and succinic acid (Yasuro Oshima Ed., "Extreme Environment Microorganism Handbook", p.231, Science Forum; BorichewskiR.M., J. Bacteriol., 93, pp.597-599 (1967) etc.).
Therefore, it is considered that many microorganisms are susceptible to L-glutamic acid, which is also an organic acid, under acidic conditions, and there has been no report that -4 O search of microorganisms showing L-glutamic acid-producing 1 ability under acidic conditions was attempted.
O All references, including any patents or patent applications, cited in this specification are hereby 00 incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the Sreferences states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of prior art Spublications are referred to herein, this reference does CI not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.
SUMMARY OF THE INVENTION The inventors of the present invention considered during the study for improvement of L-glutamic acid productivity by fermentation that inhibition of the production by L-glutamic acid accumulated in a medium at a high concentration was one of the obstructions to the improvement of productivity. For example, cells have an excretory system and an uptake system for L-glutamic acid.
However, if L-glutamic acid once excreted into the medium is incorporated into cells again, not only the production efficiency falls, but also the L-glutamic acid biosynthetic reactions are inhibited as a result. In order to avoid the inhibition of production by such accumulation of L-glutamic acid at high concentration, the inventors of the present invention screened microorganisms that can proliferate under acidic conditions and in the presence of a high concentration of L-glutamic acid. As a result, they successfully isolated microorganisms having such properties from a soil, and thus accomplished the present invention.
N \Mclboumc\Cses\Pae,,,\3900-39999P3923 I AU I Specis\P3923 I AU, I Spec fcat in 2007.10. I doc I8-0v-07 Thus, the present invention provides an isolated microorganism which can metabolize a carbon source at a pH of 3.0 to 5.0 in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source, and which has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH.
The present invention further provides a method for screening a microorganism suitable for producing L-glutamic acid by fermentation with precipitating L-glutamic acid in a liquid medium, which comprises inoculating a sample containing a microorganism into an acidic medium containing L-glutamic acid at a saturation concentration and a carbon source, and selecting a microorganism that can metabolize the carbon source.
The present invention further provides: A microorganism which can metabolize a carbon source at a specific pH in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source, and has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH.
The microorganism according to which can grow in the liquid medium.
The microorganism according to or wherein the pH is not more than The microorganism according to any one of to which has at least one of the following characteristics: the microorganism has enhanced activity of an enzyme that catalyzes a reaction for biosynthesis of L-glutamic acid; and the microorganism has decreased or deficient activity of an enzyme that catalyzes a reaction branching from a biosynthetic pathway of L-glutamic acid and producing a compound other than L-glutamic acid.
H:\rochb\Kee\2005 2 00716.doc 08/09/05 The microorganism according to wherein the enzyme that catalyzes the reaction for biosynthesis of L-glutamic acid is at least one selected from citrate synthase, phosphoenolpyruvate carboxylase and glutamate dehydrogenase.
The microorganism according to or wherein the enzyme that catalyzes the reaction branching from the biosynthetic pathway of L-glutamic acid and producing a H:\rochb\Keep\2005 2 00716.doc 08/09/05 compound other than L-glutamic acid is c-ketoglutarate dehydrogenase.
The microorganism according to any one of to wherein the microorganism belongs to the genus Enterobacter.
The microorganism according to which is Enterobacter agglomerans.
The microorganism according to which has a mutation that causes less extracellular secretion of a viscous material compared with a wild strain when cultured in a medium containing a saccharide.
A method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism as defined in any one of to in a liquid medium of which pH is adjusted to a pH at which L-glutamic acid is precipitated, to produce and accumulate L-glutamic acid and precipitate L-glutamic acid in the medium.
(11) A method for screening a microorganism suitable for producing L-glutamic acid by fermentation with precipitating L-glutamic acid in a liquid medium, which comprises inoculating a sample containing microorganisms into an acidic medium containing L-glutamic acid at a saturation concentration and a carbon source, and selecting a strain that can metabolize the carbon source.
(12) The method according to wherein a strain that can grow in the medium is selected as the strain that can metabolize the carbon source.
(13) The method according to (11) or wherein a pH of the medium is not more than 7 7 According to the method of the present invention, L- C glutamic acid can be produced by fermentation with 0 precipitating L-glutamic acid. As a result, L-glutamic 0 acid in the medium is maintained below a certain 00 concentration, and L-glutamic acid can be produced without suffering from the product inhibition by L-glutamic acid ND at a high concentration.
In the claims which follow and in the description of the invention, except where the context requires otherwise due to express language or necessary implication, the word S"comprise" or variations such as "comprises" or CA( "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
BREIF EXPLANATION OF THE DRAWINGS Fig. 1 shows a restriction map of a DNA fragment derived from Enterobacter agglomerans pTWVEK101.
Fig. 2 show comparison of the amino acid sequence deduced from the nucleotide sequence of the sucA gene derived from Enterobacter agglomerans and that derived from Escherichia coli. Upper sequence: Enterobacter agglomerans, lower sequence: Escherichia coli (the same shall apply hereafter).
Fig. 3 shows comparison of the amino acid sequence deduced from the nucleotide sequence of the sucB gene derived from Enterobacter agglomerans and that derived from Escherichia coli.
Fig. 4 shows comparison of the amino acid sequence deduced from the nucleotide sequence of the sucC gene derived from Enterobacter agglomerans and that derived from Escherichia coli.
Fig. 5 shows comparison of the amino acid sequence deduced from the nucleotide sequence of the sdhB gene derived from Enterobacter agglomerans and that derived from N \Mebout-n\Cses\Paten\39000-39999P3923 I AU, I SpccisP3923 I AU I Specification 2007. 10. 18 doc 18-Oct.07 Escherichia coli.
Fig. 6 shows construction of plasmid pMWCPG having a gltA gene, a ppc gene and a gdhA gene.
Fig. 7 shows construction of plasmid RSF-Tet having the replication origin of the broad host spectrum plasmid RSF1010 and a tetracycline resistance gene.
Fig. 8 shows construction of plasmid RSFCPG having the replication origin of the broad host spectrum plasmid RSF1010, a tetracycline resistance gene, a gltA gene, a ppc gene and a gdhA gene.
Fig. 9 shows construction of plasmid pSTVCB having a gltA gene.
DETAILED DESCRIPTION OF THE INVENTION Hereafter, the present invention will be explained in detail.
The microorganism of the present invention is a microorganism that can metabolize a carbon source at a specific pH in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source and (2) has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH.
The term "saturation concentration" means a concentration of L-glutamic acid dissolved in a liquid medium when the liquid medium is saturated with L-glutamic acid.
Hereafter, a method for screening a microorganism that can metabolize a carbon source in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source at a specific pH will be described. A sample containing microorganisms is inoculated into a liquid medium containing L-glutamic acid at a saturation concentration and a carbon source at a specific pH, and a strain that can metabolize the carbon source is selected. The specific pH is not particularly limited, but is usually not more than about 5.0, preferably not more than about 4.5, more preferably not more than about 4.3. The microorganism of the present invention is used to produce L-glutamic acid by fermentation with precipitating L-glutamic acid. If the pH is too high, it becomes difficult to allow the microorganism to produce L-glutamic acid enough for precipitation.
Therefore, pH is preferably in the aforementioned range.
If pH of an aqueous solution containing L-glutamic acid is lowered, the solubility of L-glutamic acid significantly falls around pKa of y-carboxyl group (4.25, 25 0 The solubility becomes the lowest at the isoelectric point (pH 3.2) and L-glutamic acid exceeding the amount corresponding to the saturation concentration is precipitated. While it depends on the medium composition, L-glutamic acid is usually dissolved in an amount of 10 to 20 g/L at pH 3.2, 30 to g/LatpH4.0and50to 60g/LatpH4.7, atabout30 0 C. Usually pH does not need to be made below 3.0, because the L-glutamic acid precipitating effect plateaus when pH goes below a certain value. However, pH may be below In addition, the expression that a microorganism "can metabolize the carbon source" means that it can proliferate or can consume the carbon source even though it cannot proliferate, that is, it indicates that it catabolizes carbon sources such as saccharides or organic acids. Specifically, for example, if a microorganism proliferates when cultured in a liquid medium containing L-glutamic acid at a saturation concentration at pH 5.0 to 4.0, preferably pH 4.5 to more preferably pH 4.3 to 4.0, still more preferably pH at an appropriate temperature, for example, 28°C, 37°C or 0 C for 2 to 4 days, this microorganism can metabolize the carbon source in the medium. Further, for example, even if a microorganism does not proliferate when it is cultured in a liquid medium containing L-glutamic acid at a saturation concentration at pH 5.0 to 4.0, preferably pH 4.5 to more preferably pH 4.3 to 4.0, still more preferably pH at an appropriate temperature, for example, 28 0 C, 37 0 C or 0 C for 2 to 4 days, the microorganism which consumes the carbon source in the medium is that can metabolize the carbon source in the medium.
The microorganism which can metabolize the carbon source includes a microorganism which can grow in the liquid medium.
The expression that a microorganism "can grow" means that it can proliferate or can produce L-glutamic acid even though it cannot proliferate. Specifically, for example, if a microorganism proliferates when cultured in a liquid medium containing L-glutamic acid at a saturation concentration at pH 5.0 to 4.0, preferably pH 4.5 to more preferably pH 4.3 to 4.0, still more preferably pH at an appropriate temperature, for example, 28 0 C, 37 0 C or for 2 to 4 days, this microorganism can grow in the medium.
Further, for example, even if a microorganism does not proliferate when it is cultured in a liquid synthetic medium containing L-glutamic acid at a saturation concentration at pH 5.0 to 4.0, preferably pH 4.5 to 4.0, more preferably pH 4.3 to 4.0, still more preferably pH 4.0 at an appropriate temperature, for example, 28 0 C, 37 0 C or 50 0 C for 2 to 4 days, the microorganism which increases the amount of L-glutamic acid in the medium is that can grow in the medium.
The selection described above may be repeated two or more times under the same conditions or with changing pH or the concentration of L-glutamic acid. An initial selection can be performed in a medium containing L-glutamic acid at a concentration lower than the saturation concentration, and thereafter a subsequent selection can be performed in a medium containing L-glutamic acid at a saturation concentration. Further, strains with favorable properties such as superior proliferation rate may be selected.
In addition to the property described above, the microorganism of the present invention has ability to accumulate L-glutamic acid in an amount exceeding the amount corresponding to the saturation concentration of L-glutamic acid in a liquid medium. The pH of the aforementioned liquid medium is preferably the same as or close to that of the medium used for screening a microorganism having the aforementioned property Usually, a microorganism becomes susceptible to L-glutamic acid at a high concentration as pH becomes lower.
Therefore, it is preferred that pH is not low from the viewpoint of resistance to L-glutamic acid, but low pH is preferred from the viewpoint of production of L-glutamic acid with precipitating it. To satisfy these conditions, pH may be in the range of 3 to 5, preferably 4 to 5, more preferably to 4.7, still more preferably 4.0 to 4.5, particularly preferably 4.0 to 4.3.
As the microorganism of the present invention or breeding materials therefor, there can be mentioned, for example, microorganisms belonging to the genus Enterobacter, Klebsiella, Serratia, Pantoea, Erwinia, Escherichia, Corynebacterium, Alicyclobacillus, Bacillus, Saccharomyces or the like. Among these, microorganisms belonging to the genus Enterobacter are preferred. Hereafter, the microorganism of the present invention will be explained mainly for microorganisms belonging to the genus Enterobacter, but the present invention can be applied to microorganism belonging to other genera and not limited to the genus Enterobacter.
As microorganisms belonging to the Enterobacter, there can be specifically mentioned Enterobacter agglomerans, preferably the Enterobacter agglomerans AJ13355 strain.
This strain was isolated from a soil in Iwata-shi, Shizuoka, Japan as a strain that can proliferate in a medium containing L-glutamic acid and a carbon source at low pH.
The physiological properties of AJ13355 are as follows: Gram staining: negative Behavior against oxygen: facultative anaerobic Catalase: positive Oxidase: negative Nitrate-reducing ability: negative Voges-Proskauer test: positive Methyl Red test: negative Urease: negative Indole production: positive Motility: motile (11) H 2 S production in TSI medium: weakly active (12) 3-galactosidase: positive (13) Saccharide-assimilating property: Arabinose: positive Sucrose: positive Lactose: positive Xylose: positive Sorbitol: positive Inositol: positive Trehalose: positive Maltose: positive Glucose: positive Adonitol: negative Raffinose: positive Salicin: negative Melibiose: positive (14) Glycerol-assimilating property: positive Organic acid-assimilating property: Citric acid: positive Tartaric acid: negative Gluconic acid: positive Acetic acid: positive Malonic acid: negative (16) Arginine dehydratase: negative (17) Ornithine decarboxylase: negative (18) Lysine decarboxylase: negative (19) Phenylalanine deaminase: negative Pigment formation: yellow (21) Gelatin liquefaction ability: positive (22) Growth pH: growth is possible at pH 4.0, good growth at pH 4.5 to 7 (23) Growth temperature: good growth at 25 0 C, good growth at 30 0 C, good growth at 37 0 C, growth is possible at 42 0 C, growth is not possible at Based on these bacteriological properties, AJ13355 was determined as Enterobacter agglomerans.
The Enterobacter agglomerans AJ13355 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305-8566, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan) on February 19, 1998 and received an accession number of FERM P-16644.
It was then transferred to an international deposition under the provisions of Budapest Treaty on January 11, 1999 and received an accession number of FERM BP-6614.
The microorganism of the present invention may be a microorganism originally having L-glutamic acid-producing ability or one having L-glutamic acid-producing ability imparted or enhanced by breeding through use of mutation treatment, recombinant DNA techniques or the like.
L-Glutamic acid-producing ability can be imparted or enhanced by, for example, increasing activity of an enzyme that catalyzes a reaction for biosynthesis of L-glutamic acid.
L-Glutamic acid-producing ability can also be enhanced by decreasing activity of an enzyme that catalyzes a reaction branching from the biosynthetic pathway of L-glutamic acid and producing a compound other than L-glutamic acid, or making the activity deficient.
As enzymes that catalyze a reaction for biosynthesis of L-glutamic acid, there can be mentioned glutamate dehydrogenase (hereafter, also referred to as "GDH"), glutamine synthetase, glutamate synthase, isocitrate dehydrogenase, aconitate hydratase, citrate synthase (hereafter, also referred to as phosphoenolpyruvate carboxylase (hereafter, also referred to as "PEPC"), pyruvate dehydrogenase, pyruvate kinase, enolase, phosphoglyceromutase, phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, triosephosphate isomerase, fructose bisphosphate aldolase, phosphofructokinase, glucose phosphate isomerase and so forth. Among these enzymes, one, two or three of CS, PEPC and GDH are preferred. Further, it is preferred that the activities of all the three enzymes, CS, PEPC and GDH, are enhanced in the microorganism of the present invention. In particular, CS of Brevibacteriumlactofermentum is preferred, because it does not suffer from inhibition by a-ketoglutaric acid, L-glutamic acid and NADH.
In order to enhance the activity of CS, PEPC or GDH, for example, a gene coding for CS, PEPC or GDH may be cloned on an appropriate plasmid and a host microorganism may be transformed with the obtained plasmid. The copy number of the gene coding for CS, PEPC or GDH (hereafter, abbreviated as "gltA gene", "ppc gene" and "gdhA gene", respectively) in the transformed strain cell increases, resulting in the increase of the activity of CS, PEPC or GDH.
The cloned gltA gene, ppc gene and gdhA gene are introduced into the aforementioned starting parent strain solely or in combination of arbitrary two or three kinds of them. When two or three kinds of the genes are introduced, two or three kinds of the genes may be cloned on one kind of plasmid and introduced into the host, or separately cloned on two or three kinds of plasmids that can coexist and introduced into the host.
Two or more kinds of genes coding for enzymes of the same kind, but derived from different microorganisms may be introduced into the same host.
The plasmids described above are not particularly limited so long as they are autonomously replicable in cells of a microorganism belonging to, for example, the genus Enterobacter or the like, but, for example, there can be mentioned pUC19, pUC18, pBR322, pHSG299, pHSG298, pHSG399, pH SG398, RSF1010, pMW119, pMW118, pMW219, pMW218, pACYC177, pACYC184 and so forth. Besides these, vectors of phage DNA can also be used.
Transformation can be performed by, for example, the method of D.M. Morrison (Methods in Enzymology, 68, 326 (1979)), the method wherein permeability of DNA is increased by treating recipient bacterium cells with calcium chloride (Mandel M. and Higa J. Mol. Biol., 53, 159 (1970)), the electroporation (Miller "A Short Course in Bacterial Genetics", Cold Spring Harbor Laboratory Press, U.S.A. 1992) or the like.
The activity of CS, PEPC or GDH can also be increased by allowing multiple copies of a gltA gene, a ppc gene or a gdhA gene to be present on chromosomal DNA of the aforementioned starting parent strain to be a host. In order to introduce multiple copies of the gltA gene, the ppc gene or the gdhA gene on chromosomal DNA of a microorganism belonging to the genus Enterobacter or the like, a sequence of which multiple copies are present on the chromosomal DNA, such as repetitive DNA and inverted repeats present at termini of a transposable element, can be used.
Alternatively, multiple copies of the genes can be introduced onto chromosomal DNA by utilizing transfer of a transposon containing the gltA gene, the ppc gene or the gdhA gene. As a result, the copy number of the gltA gene, the ppc gene or the gdhA gene in a transformed strain cell is increased, and thus the activity of CS, PEPC or GDH is increased.
As organisms to be a source of the gltA gene, the ppc gene or the gdhA gene of which copy number is increased, any organism can be used so long as it has activity of CS, PEPC or GDH. Inter alia, bacteria, which are prokaryotes, for example, those belonging to the genus Enterobacter, Klebsiella, Erwinia, Pantoea, Serratia, Escherichia, Corynebacterium, Brevibacterium and Bacillus are preferred.
As specific examples, there can be mentioned Escherichia coli, Brevibacterium lactofermentum and so forth. The gltA gene, the ppc gene and the gdhA gene can be obtained from chromosomal DNA of the microorganisms described above.
The gltA gene, the ppc gene and the gdhA gene can be obtained by using a mutant strain which is deficient in the activity of CS, PEPC or GDH to isolate a DNA fragment which complements the auxotrophy from chromosomal DNA of the aforementioned microorganisms. Since the nucleotide sequences of these genes of Escherichia and Corynebacterium bacteria have already been elucidated (Biochemistry, 22, pp.5243-5249 (1983); J. Biochem., 95, pp.909-916 (1984); Gene, 27, pp.193-199 (1984); Microbiology, 140, pp.1817- 1828 (1994); Mol. Gen. Genet., 218, pp.
330 339 (1989); Molecular Microbiology, 6, pp.317-326 (1992)), theycan also be obtained by PCR utilizing primers synthesized based on each nucleotide sequence and chromosomal DNA as a template.
The activity of CS, PEPC or GDH can also be increased by enhancing the expression of the gltA gene, the ppc gene or the gdhA gene besides the aforementioned amplification of the genes. For example, the expression can be enhanced by replacing a promoter for the gltA gene, the ppc gene or the gdhA gene with other stronger promoters. For example, lac promoter, trp promoter, trc promoter, tac promoter, P.
promoter and P, promoter of the lamda phage and so forth are known as strong promoters. The gltA gene, the ppc gene and the gdhA gene of which promoter is replaced are cloned on a plasmid and introduced into the host microorganism, or introduced onto the chromosomal DNA of the host microorganism by using repetitive DNA, inverted repeats, transposon or the like.
The activity of CS, PEPC or GDH can also be enhanced by replacing the promoter of the gltA gene, the ppc gene or the gdhA gene on the chromosome with other stronger promoters (see WO 87/03006 and Japanese Patent Application Laid-open No. 61-268183), or inserting a strong promoter in the upstream of the coding sequence of each gene (see Gene, 29, pp.231-241 (1984)). Specifically, homologous recombination can be performed between DNA containing the gltA gene, the ppc gene or the gdhA gene of which promoter is replaced with a stronger one or a part thereof and the corresponding gene on the chromosome.
Examples of the enzyme which catalyze a reaction branching from the biosynthetic pathway of the L-glutamic acid and producing a compound other than L-glutamic acid include a-ketoglutarate dehydrogenase (hereafter, also referred to as "aKGDH"), isocitrate lyase, phosphate acetyltransferase, acetate kinase, acetohydroxy acid synthase, acetolactate synthase, formate acetyltransferase, lactate dehydrogenase, glutamate decarboxylase, 1pyrroline dehydrogenase and so forth. Among these enzymes, cKGDH is preferred.
In order to obtain decrease or deficiency of the activity of the aforementioned enzyme in a microorganism belonging to the genus Enterobacter or the like, mutation causing decrease or deficiency of the intracellular activity of the enzyme can be introduced into the gene of the aforementioned enzyme by a usual mutagenesis or genetic engineering method.
Examples of the mutagenesis method include, for example, methods utilizing irradiation with X-ray or ultraviolet ray, methods utilizing treatment with a mutagenic agent such as N-methyl-N'-nitro-Nnitrosoguanidine, and so forth. The site where the mutation is introduced to the gene may be in a coding region coding for an enzyme protein, or a region for regulating expression such as a promoter.
Examples of the genetic engineering methods include, for example, methods utilizing gene recombination, transduction, cell fusion and so forth. For example, a drug resistance gene is inserted into a cloned target gene to prepare a gene that has lost its function (defective gene).
Subsequently, this defective gene is introduced into a cell of a host microorganism, and the target gene on the chromosome is replaced with the aforementioned defective gene by utilizing homologous recombination (gene disruption).
Decrease or deficiency of intracellular activity of the target enzyme and the degree of decrease of the activity can be determined by measuring the enzyme activity of a cell extract or a purified fraction thereof obtained from a candidate strain and comparing with that of a wild strain.
For example, the CKGDH activity can be measured by the method of Reed et al. (Reed L.J. and Mukherjee Methods in Enzymology, 13, pp.55-61 (1969)).
Depending on the target enzyme, the target mutant strain can be selected based on the phenotype of the mutant strain. For example, a mutant strain which is deficient in the aKGDH activity or decreases in the aKGDH activity cannot proliferate or shows a markedly reduced proliferation rate in a minimal medium containing glucose or a minimal medium containing acetic acid or L-glutamic acid as an exclusive carbon source under aerobic conditions. However, normal proliferation is enabled even under the same condition by adding succinic acid or lysine, methionine and diaminopimelic acid to a minimal medium containing glucose.
By utilizing these phenomena as indicators, mutant strains with decreased aKGDH activity or deficient in the activity can be selected.
A method for preparing the aKGDH gene deficient strain of Brevibacterium lactofermentum by utilizing homologous recombination is described in detail in WO 95/34672.
Similar methods can be applied to the other microorganisms.
Further, techniques such as cloning of genes and cleavage and ligation of DNA, transformation and so forth are described in detail in Molecular Cloning, 2nd Edition, Cold Spring Harbor Press, 1989 and so forth.
As a specific example of a mutant strain deficient in aKGDH activity or with decreased aKGDH activity obtained as described above, there can be mentioned Enterobacter agglomerans AJ13356. Enterobacter agglomerans AJ13356 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305-8566, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan) on February 19, 1998 and received an accession number of FERM P-16645. It was then transferred to an international deposition under the provisions of Budapest Treaty on January 11, 1999 and received an accession number of FERM BP-6615. The Enterobacter agglomerans AJ13356 is deficient in aKGDH activity as a result of disruption of the aKGDH-E1 subunit gene (sucA).
When Enterobacter agglomerans, an example of the microorganism used in the present invention, is cultured in a medium containing a saccharide, a viscous material is extracellularly secreted, resulting in low operation efficiency. Therefore, when Enterobacter agglomerans having such a property of secreting the viscous material is used, it is preferable to use a mutant strain that secretes less the viscous material compared with a wild strain.
Examples of mutagenesis methods include, for example, methods utilizing irradiation with X ray or ultraviolet ray, method utilizing treatment with a mutagenic agent such as N-methyl-N'-nitro-N-nitrosoguanidine and so forth. A mutant strain with decreased secretion of the viscous material can be selected by inoculating mutagenized bacterial cells in a medium containing a saccharide, for example, LB medium plate containing 5 g/L of glucose, culturing them with tilting the plate about 45 degrees and selecting a colony which does not show flowing down of liquid.
In the present invention, impartation or enhancement of L-glutamic acid-producing ability and impartation of other favorable properties such as mutation for less viscous material secretion described above can be carried out in an arbitrary order.
By culturing the microorganism of the present invention in a liquid medium of which pH is adjusted to a pH at which L-glutamic acid is precipitated, L-glutamic acid can be produced and accumulated with precipitating it in the medium. L-Glutamic acid can also be precipitated by starting the culture at a neutral pH and then ending it at a pH at which L-glutamic acid is precipitated.
The pH at which L-glutamic acid is precipitated means one at which L-glutamic acid is precipitated when the microorganism produces and accumulates L-glutamic acid.
As the aforementioned medium, a usual nutrient medium containing a carbon source, a nitrogen source, mineral salts and organic trace nutrients such as amino acids and vitamins as required can be used so long as pH is adjusted to a pH at which L-glutamic acid is precipitated. Either a synthetic medium or a natural medium can be used. The carbon source and the nitrogen source used in the medium can be any ones so long as they can be used by the cultured strain.
As the carbon source, saccharides such as glucose, glycerol, fructose, sucrose, maltose, mannose, galactose, starch hydrolysate and molasses are used. In addition, organic acids such as acetic acid and citric acid may be used each alone or in combination with another carbon source.
As the nitrogen source, ammonia, ammonium salts such as ammonium sulfate, ammonium carbonate, ammonium chloride, ammonium phosphate and ammonium acetate, nitrates and so forth are used.
As the organic trace nutrients, amino acids, vitamins, fatty acids, nucleic acids, those containing these substances such as peptone, casamino acid, yeast extract and soybean protein decomposition products are used. When an auxotrophic mutant strain that requires an amino acid and so forth for metabolization or growth is used, the required nutrient must be supplemented.
As mineral salts, phosphates, magnesium salts, calcium salts, iron salts, manganese salts and so forth are used.
As for the culture method, aeration culture is usually performed with controlling the fermentation temperature to be 20 to 42 0 C and pH to be 3 to 5, preferably 4 to 5, more preferably 4 to 4.7, particularly preferably 4 to 4.5. Thus, after about 10 hours to 4 days of culture, a substantial amount of L-glutamic acid is accumulated in the culture.
Accumulated L-glutamic acid exceeding the amount corresponding to the saturation concentration is precipitated in the medium.
After completion of the culture, L-glutamic acid precipitated in the culture can be collected by centrifugation, filtration or the like. L-Glutamic acid dissolved in the medium can be collected according to known methods. For example, the L-glutamic acid can be isolated by concentrating the culture broth to crystallize it or isolated by ion exchange chromatography or the like. L- Glutamic acid precipitated in the culture broth may be isolated together with L-glutamic acid that have been dissolved in the medium after it is crystallized.
According to the method of the present invention, L-glutamic acid exceeding the amount corresponding to the saturation concentration is precipitated, and the concentration of L-glutamic acid dissolved in the medium is maintained at a constant level. Therefore, influence of L-glutamic acid at a high concentration on microorganisms can be reduced. Accordingly, it becomes possible to breed a microorganism having further improved L-glutamic acidproducing ability. Further, since L-glutamic acid is precipitated as crystals, acidification of the culture broth by accumulation of L-glutamic acid is suppressed, and therefore the amount of alkali used for maintaining pH of the culture can significantly be reduced.
EXAMPLES
Hereafter, the present invention will be more specifically explained with reference to the following examples.
Screening of microorganism having L-glutamic acid resistance in acidic environment Screening of a microorganism having L-glutamic acid resistance in an acidic environment was performed as follows.
Each of about 500 samples obtained from nature including soil, fruits, plant bodies, river water in an amount of 1 g was suspended in 5 mL of sterilized water, of which 200 LtL was coated on 20 mL of solid medium of which pH was adjusted to with HC1. The composition of the medium was as follows: 3 g/L.of glucose, 1 g/L of (NH 4 2
SO
4 0.2 g/L of MgSO 4 7H 2 0, g/L of KH 2 PO,, 0.2 g/L of NaC1, 0.1 g/L of CaCl 2 -7H 2 0, 0.01 g/L of FeSO,7H20, 0.01 g/L of MnSO4H20, 0.72 mg/L of ZnSO'2HO, 0.64 mg/L of CuSO 4 5HO2, 0.72 mg/L of CoC12-6H2, 0.4 mg/L of boric acid, 1.2 mg/L of Na 2
MOO
4 2H 2 O, 50 ug/L of biotin, tg/L of calcium pantothenate, 50 ,ug/L of folic acid, 50 ug/L of inositol, 50 g/L of niacin, 50 jtg/L of p-aminobenzoic acid, 50 ,tg/L of pyridoxine hydrochloride, 50 tg/L of riboflavin, 50 ug/L of thiamine hydrochloride, 50 mg/L of cycloheximide, 20 g/L of agar.
The media plated on which the above samples were plated were incubated at 28 0 C, 37 0 C or 50 0 C for 2 to 4 days and 378 strains each forming a colony were obtained.
Subsequently, each of the strains obtained as described above was inoculated in a test tube of 16.5 cm in length and 14 mm in diameter containing 3 mL of liquid medium (adjusted to pH 4.0 with HC1) containing a saturation concentration of L-glutamic acid and cultured at 28 0 C, 37 0
C
or 50 0 C for 24 hours to 3 days with shaking. Then, the grown strains were selected. The composition of the aforementioned medium was follows: 40 g/L of glucose, 20 g/L of (NH,) 2 SO, 0.5 g/L of MgSO 4 7HO, 2 g/L of KHPO 4 0.5 g/L of NaC1, 0.25 g/L of CaC1 2 -7HO, 0.02 g/L of FeSO 4 7H 2 0, 0.02 g/L of MnSO 4 4H20, 0.72 mg/L of ZnSO*2H 2 0, 0.64 mg/L of CuS0 4 5H 2 0, 0.72 mg/L of CoCl 6H 2 0, 0.4 mg/L of boric acid, 1.2 mg/L of Na 2 MoO 4 2HO, 2 g/L of yeast extract.
Thus, 78 strains of microorganisms having L-glutamic acid resistance in an acidic environment were successfully obtained.
Selection of strains with superior growth rate in acidic environment from microorganisms having L-glutamic acid resistance The various microorganisms having L-glutamic acid resistance in an acidic environment obtained as described above were each inoculated into a test tube of 16.5 cm in length and 14 mm in diameter containing 3 mL of medium (adjusted to pH 4.0 with HC1) obtained by adding 20 g/L of glutamic acid and 2 g/L of glucose to M9 medium (Sambrook, Fritsh, E.F. andManiatis, "Molecular Cloning", Cold Spring Harbor Laboratory Press, 1989), and the turbidity of the medium was measured in the time course to select strains with a favorable growth rate. As a result, as a strain showing favorable growth, the AJ13355 strain was obtained from a soil in Iwata-shi, Shizuoka, Japan. This strain was determined as Enterobacter agglomerans based on its bacteriological properties described above.
Acquisition of strain with less viscous material secretion from Enterobacter agglomerans AJ13355 strain Since the Enterobacter agglomerans AJ13355 strain extracellularly secretes a viscous material when cultured in a medium containing a saccharide, operation efficiency is not favorable. Therefore, a strain with less viscous material secretion was obtained by the ultraviolet irradiation method (Miller, J.H. et al., "A Short Course in Bacterial Genetics; Laboratory Manual", p.150, Cold Spring Harbor Laboratory Press, 1992).
The Enterobacter agglomerans AJ13355 strain was irradiated with ultraviolet ray for 2 minutes at the position cm away from a 60-W ultraviolet lamp and cultured in LB medium overnight to fix mutation. The mutagenized strain was diluted and inoculated in LB medium containing 5 g/L of glucose and 20 g/L of agar so that about 100 colonies per plate would emerge and cultured at 30 0 C overnight with tilting the plate about 45 degrees, and then 20 colonies showing no flowing down of the viscous material were selected.
As a strain satisfying conditions that no revertant emerged even after 5 times of subculture in LB medium containing 5 g/L of glucose and 20 g/L of agar, and that there should be observed growth equivalent to the parent strain in LB medium, LB medium containing 5 g/L of glucose and M9 medium (Sambrook, J. et al., Molecular Cloning, 2nd Edition, Cold Spring Harbor Press, 1989) to which 20 g/L of L-glutamic acid and 2 g/L of glucose were added and of which pH was adjusted to 4.5 with HC1, SC17 strain was selected from the strains selected above.
Construction of glutamic acid-producing bacterium from Enterobacter agglomerans SC17 strain Preparation of aKGDH deficient strain from Enterobacter agglomerans SC17 strain A strain deficient in aKGDH and with enhanced Lglutamic acid biosynthetic system was prepared from the Enterobacter agglomerans SC17 strain.
Cloning of aKGDH gene (hereafter, referred to as "sucAB") of Enterobacter agglomerans AJ13355 strain The sucAB gene of the Enterobacter agglomerans AJ13355 strain was cloned by selecting a DNA fragment complementing the acetic acid-unassimilating property of the aKGDH-El subunit gene (hereafter, referred to as "sucA") deficient strain of Escherichia coli from chromosomal DNA of the Enterobacter agglomerans AJ13355 strain.
The chromosomal DNA of the Enterobacter agglomerans AJ13355 strain was isolated by a method usually employed when chromosomal DNA is extracted from Escherichia coli (Text for Bioengineering Experiments, Edited by the Society for Bioscience and Bioengineering, Japan, pp.97-98, Baifukan, 1992). The pTWV228 (resistant to ampicillin) used as a vector was commercially available one from Takara Shuzo Co., Ltd.
The chromosomal DNA of the AJ13355 strain digested with EcoT221 and pTWV228 digested with PstI were ligated by using T4 ligase and used to transform the sucA deficient Escherichia coli JRG465 strain (Herbert, J. et al., Mol. Gen.
Genetics, 105, 182 (1969)). A strain growing in an acetate minimal medium was selected from the transformant strains obtained above, and a plasmid was extracted from it and designated as pTWVEK101. TheEscherichia coli JRG465 strain harboring pTWVEK101 recovered auxotrophy for succinic acid or L-lysine and L-methionine besides the acetic acidassimilating property. This suggests that pTWVEK101 contains the sucA gene of Enterobacter agglomerans.
Fig. 1 shows the restriction map of a DNA fragment derived from Enterobacter agglomerans in pTWVEK101. The determined nucleotide sequence of the hatched portion in Fig.
1 is shown as SEQ ID NO: 1. In this sequence, nucleotide sequences considered to be two full length ORFs and two nucleotide sequences considered to be partial sequences of the ORFs were found. SEQ ID NOS: 2 to 5 show amino acid sequences that can be encoded by these ORFs or partial sequences in an order from the 5' end. As a result of homology search for these, it was revealed that the portion of which nucleotide sequences were determined contained a 3'-end partial sequence of the succinate dehydrogenase iron-sulfur protein gene (sdhB), full length sucA and aKGDH-E2 subunit gene (sucB), and 5'-end partial sequence of the succinyl CoA synthetase P subunit gene (sucC). The results of comparison of the amino acid sequences deduced from these nucleotide sequences with those derived from Escherichia coli (Eur. J.
Biochem., 141, pp.351-359 (1984); Eur. J. Biochem., 141, pp.361-374 (1984); Biochemistry, 24, pp.6245-6252 (1985)) are shown in Figs. 2 to 5. Thus, the amino acid sequences each showed very high homology. In addition, it was found that a cluster of sdhB-sucA-sucB-sucC was constituted on the chromosome of Enterobacter agglomerans as in Escherichia coli (Eur. J. Biochem., 141, pp.351-359 (1984); Eur. J.
Biochem., 141, pp.361-374 (1984); Biochemistry, 24, pp.6245-6252 (1985)).
(ii) Acquisition of aKGDH deficient strain derived from Enterobacter agglomerans SC17 strain The homologous recombination was performed by using the sucAB gene of Enterobacter agglomerans obtained as described above to obtain an aKGDH deficient strain of Enterobacter agglomerans.
After pTWVEK101 was digested with SphI to excise a fragment containing sucA, the fragment was blunt-ended with Klenow fragment (Takara Shuzo Co., Ltd.) and ligated with pBR322 digested with EcoRI and blunt-ended with Klenow fragment, by using T4 DNA ligase (Takara Shuzo Co., Ltd.).
The obtained plasmid was digested at the restriction enzyme BglII recognition site positioned substantially at the center of sucA by using this enzyme, blunt-ended with Klenow fragment, and then ligated again by using T4 DNA ligase. It was considered that the sucA gene did not function because a frameshift mutation was introduced into sucA of the plasmid newly constructed through the above procedure.
The plasmid constructed as described above was digested with a restriction enzyme ApaLI, and subjected to agarose gel electrophoresis to recover a DNA fragment containing sucA into which the frameshift mutation was introduced and a tetracycline resistance gene derived from pBR322. The recovered DNA fragment was ligated again by using T4 DNA ligase to construct a plasmid for disrupting the aKGDH gene.
The plasmid for disrupting the cKGDH gene obtained as described above was used to transform the Enterobacter agglomerans SC17 strain by electroporation (Miller, J.H., "A Short Course in Bacterial Genetics; Handbook", p.279, Cold Spring Harbor Laboratory Press, 1992), and a strain wherein sucA on the chromosome was replaced with a mutant type one by homologous recombination of the plasmid was obtained by using the tetracycline resistance as an indicator.
The obtained strain was designated as SC17sucA strain.
In order to confirm that the SC17sucA strain was deficient in the aKGDH activity, the enzyme activity was measured by the method of Reed et al. (Reed, L.J. and Mukherjee, Methods in Enzymology, 13, pp.55-61, (1969)) by using cells of the strain cultured in LB medium until the logarithmic growth phase. As a result, aKGDH activity of 0.073 (AABS/min/mg protein) was detected from the SC17 strain, whereas no aKGDH activity was detected from the SC17sucA strain, and thus it was confirmed that the sucA was deficient as purposed.
Enhancement of L-glutamic acid biosynthetic system of Enterobacter agglomerans SCl7sucA strain Subsequently, a citrate synthase gene, a phosphoenolpyruvate carboxylase gene and a glutamate dehydrogenase gene derived from Escherichia coli were introduced into the SC17sucA strain.
Preparation of plasmid having gltA gene, ppc gene and gdhA gene derived from Escherichia coli The procedures of preparing a plasmid having a gltA gene, a ppc gene and a gdhA gene will be explained by referring to Figs. 6 and 7.
A plasmid having a gdhA gene derived from Escherichia coli, pBRGDH (Japanese Patent Application Laid-open No.
7-203980), was digested with HindIII and SphI, the both ends were blunt-ended by the T4 DNA polymerase treatment, and then the DNA fragment having the gdhA gene was purified and recovered. Separately, a plasmid having a gltA gene and a ppc gene derived fromEscherichia coli, pMWCP (WO 97/08294), was digested with XbaI, and then the both ends were blunt-ended by using T4 DNA polymerase. This was mixed with the above purified DNA fragment having the gdhA gene and ligated by using T4 ligase to obtain a plasmid pMWCPG,.which corresponded to pMWCP further containing the gdhA gene (Fig.
6).
At the same time, the plasmid pVIC40 (Japanese Patent Application Laid-open No. 8-047397) having the replication origin of the broad host spectrum plasmid RSF1010 was digested with NotI, treated with T4 DNA polymerase and digested with PstI. pBR322 was digested with EcoT14I, treated with T4 DNA polymerase and digested with PstI. The both products were mixed and ligated by using T4 ligase to obtain a plasmid RSF-Tet having the replication origin of RSF1010 and a tetracycline resistance gene (Fig. 7).
Subsequently, pMWCPG was digested with EcoRI and PstI, and a DNA fragment having the gltA gene, the ppc gene and the gdhA gene was purified and recovered. RSF-Tet was similarly digested with EcoRI and PstI, and a DNA fragment having the replication origin of RSF1010 was purified and recovered. The both products were mixed and ligated by using T4 ligase to obtain a plasmid RSFCPG, which corresponded to RSF-Tet containing the gltA gene, the ppc gene and the gdhA gene (Fig. It was confirmed that the obtained plasmid RSFCPG expressed.the gltA gene, the ppc gene and the gdhA gene, by the complementation of the auxotrophy of the gltA, ppc or gdhA gene deficient strain derived from Escherichia coli and measurement of each enzyme activity.
(ii) Preparation of plasmid having gltA gene derived from Brevibacterium lactofermentum A plasmid having the gltA gene derived from Brevibacterium lactofermentum was constructed as follows.
PCR was performed by using the primer DNAs having the nucleotide sequences represented by SEQ ID NOS: 6 and 7, which were prepared based on the nucleotide sequence of the Corynebacterium glutamicum gltA gene (Microbiology, 140, pp.1817-1828 (1994)), and chromosomal DNA of Brevibacterium lactofermentum ATCC13869 as a template to obtain a gltA gene fragment of about 3 kb. This fragment inserted into a plasmid pHSG399 (purchased from Takara Shuzo Co., Ltd.) digested with SmaI to obtain a plasmid pHSGCB (Fig. Subsequently, pHSGCB was digested with HindIII, and the excised gltA gene fragment of about 3 kb was inserted into a plasmid pSTV29 (purchased from Takara Shuzo Co., Ltd.) digested with HindIII to obtain a plasmid pSTVCB (Fig. It was confirmed that the obtained plasmid pSTVCB expressed the gltA gene, by measuring the enzyme activity in the Enterobacter agglomerans AJ13355 strain.
(iii) Introduction of RSFCPG and pSTVCB into SC17sucA strain The Enterobacter agglomerans SC17sucA strain was transformed with RSFCPG by electroporation to obtain a transformant SC17sucA/RSFCPG strain having tetracycline resistance. Further, the SC17sucA/RSFCPG strain was transformed with pSTVCB by electroporation to obtain a transformant SC17sucA/RSFCPG+pSTVCB strain having chloramphenicol resistance.
Acquisition of strain with improved resistance to Lglutamic acid in low pH environment A strain with improved resistance to L-glutamic acid at a high concentration in a low pH environment (hereafter, also referred to as "high-concentration Glu-resistant strain at low pH") was isolated from the Enterobacter agglomerans SC17sucA/RSFCPG+pSTVCB strain.
The SC17sucA/RSFCPG+pSTVCB strain was cultured overnight at 30 0 C in LBG medium (10 g/L of tryptone, 5 g/L of yeast extract, 10 g/L of NaCi, 5 g/L of glucose), and the cells washed with saline was appropriately diluted and plated on an M9-E medium (4 g/L of glucose, 17 g/L of Na 2 HPO-12H 2 0, 3 g/L of KH,PO 4 0.5 g/L of NaCl, 1 g/L of NH 4 C1, 10 mM of MgSO,, 10 ,tM of CaCld, 50 mg/L of L-lysine, 50 mg/L of Lmethionine, 50 mg/L of DL-diaminopimelic acid, 25 mg/L of tetracycline, 25 mg/L of chloramphenicol, 30 g/L of Lglutamic acid, adjusted to pH 4.5 with aqueous ammonia) plate.
The colony emerged after culture at 32 0 C for 2 days was obtained as a high-concentration Glu-resistant strain at low pH.
For the obtained strain, growth level in M9-E liquid medium was measured and L-glutamic acid-producing ability was tested in a 50-ml volume large test tube containing ml of L-glutamic acid production test medium (40 g/L of glucose, 20 g/L of (NHJ),SO 4 0.5 g/L of MgSO-7H 2 O, 2 g/L of
KH
2
PO
4 0.5 g/L of NaCl, 0.25 g/L of CaC12-7H 2 0, 0.02 g/L of FeSO 4 *7H20, 0.02 g/L of MnSO,-4H 2 0, 0.72 mg/L of ZnSO 4 -2H20, 0.64 mg/L of CuSO 4 5H 2 O, 0.72 mg/L of CoC12-6H 2 O, 0.4 mg/L of boric acid, 1.2 mg/L of NaMoO 4 2H 2 O, 2 g/L of yeast extract, 200 mg/L of L-lysine hydrochloride, 200 mg/L of L-methionine, 200 mg/L of DL-a,e-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride, 25 mg/L of chloramphenicol). A strain that exhibited the best growth level and the same L-glutamic acid producing ability as that of its parent strain, the SC17/RSFCPG+pSTVCB strain, was designated as Enterobacter agglomerans AJ13601. The AJ13601 strain was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305-8566, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan) on August 18, 1999 and received an accession number of FERM P-17516. It was then transferred to an international deposition under the provisions of Budapest Treaty on July 6, 2000 and received an accession number of FERM BP-7207.
Culture of Enterobacter agglomerans AJ13601 strain for L-glutamic acid production (1) The Enterobacter agglomerans AJ13601 strain was inoculated into a 1-L jar fermenter containing 300 ml of medium containing 40 g/L of glucose, 20 g/L of (NH 4 g/L of MgSO 4 7H 2 0, 2 g/L of KH 2 PO,, 0.5 g/L of NaC1, 0.25 g/L of CaCl 2 -7H 2 0, 0.02 g/L of FeSO,7H 2 0, 0.02 g/L of MnSO- 4
H
2
O,
0.72 mg/L of ZnSO 4 2H 2 O, 0.64 mg/L of CuSO 4 -5H 2 0.72 mg/L of CoC1 2 6H 2 O, 0.4 mg/L of boric acid, 1.2 mg/L of Na 2 MoO 4 2HO, 2 g/L of yeast extract, 200 mg/L of L-lysine hydrochloride, 200 mg/L of L-methionine, 200 mg/L of DL-ae-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol, and cultured at 34 0 C and pH 6.0 for 14 hours.
The culture pH was controlled by introducing ammonia gas into the medium.
The culture obtained as described above was centrifuged at 5000 rpm for 10 minutes, and the collected cells were inoculated into a 1-L jar fermenter containing 300 ml of medium containing 40 g/L of glucose, 5 g/L of
(NH,)
2
SO
4 1.5 g/L of MgSO,7H 2 0, 6 g/L of KH 2
PO
4 1.5 g/L of NaCI, 0.75 g/L of CaCl27H 2 O, 0.06 g/L of FeSO,7H 2 0, 0.06 g/L of MnSO,4H20, 2.16 mg/L of ZnSO 4 2H 2 0, 1.92 mg/L of CuSO 4 5H 2 0, 2.16 mg/L of CoC1 2 6H 2 0, 1.2 mg/L of boric acid, 3.6 mg/L of Na 2 MoO 4 2H20, 6 g/L of yeast extract, 600 mg/L of L-lysine hydrochloride, 600 mg/L of L-methionine, 600 mg/L of DLa,e-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol and cultured at 34°C and pH 4.5 to perform culture for L-glutamic acid production. The culture pH was controlled by introducing ammonia gas into the medium. As the initially added glucose was depleted, 600 g/L of glucose was continuously added.
As a result of the culture for L-glutamic acid production performed for 50 hours as described above, a substantial amount of L-glutamic acid crystals were precipitated in the jar fermenter. Table 1 shows the concentration of L-glutamic acid dissolved in the culture broth at that time and the L-glutamic acid concentration measured by dissolving the crystals in 2 M potassium hydroxide. L-Glutamic acid crystals were collected from the culture by decantation after the culture was left stood.
Table 1 Concentration of L-glutamic acid 51 g/L dissolved in culture broth Amount of L-glutamic acid 67 g/L precipitated as crystals Concentration of L-glutamic acid measured b dissolvin118 g/L measured by dissolving crystals Culture of Enterobacter agglomerans AJ13601 strain for L-glutamic acid production (2) The following experiment was performed in order to confirm that the Enterobacter agglomerans AJ13601 strain still had L-glutamic acid-producing ability even under the condition that L-glutamic acid crystals were present.
The Enterobacter agglomerans AJ13601 strain was inoculated into a 1-L jar fermenter containing 300 ml of medium containing 40 g/L of glucose, 20 g/L of (NH, 4
)SO
4 g/L of MgSO-7H 2 O, 2 g/L of KH 2
PO
4 0.5 g/L of NaCI, 0.25 g/L of CaC1-7H 2 O, 0.02 g/L of FeSO 4 7H 2 O, 0.02 g/L of MnSO.4H 2
O,
0.72 mg/L of ZnSO 4 2HO, 0.64 mg/L of CuSO,-5H 2 0, 0.72 mg/L of CoC12-6HO, 0.4 mg/L of boric acid, 1.2 mg/L of Na 2 MoO4-2HO, 2 g/L of yeast extract, 200 mg/L of L-lysine hydrochloride, 200 mg/L of L-methionine, 200 mg/L of DL-a,e-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol, and cultured at 34 C at pH 6.0 for 14 hours.
The culture pH was controlled by bubbling the medium with ammonia gas. The culture obtained as described above was centrifuged at 5000 rpm for 10 minutes, and then the collected cells were cultured in a medium where L-glutamic acid was present as crystals. The used medium contained 40 g/L of glucose, 5 g/L of (NH 4 2
SO
4 1.5 g/L of MgSO 4 -7HO0, 6 g/L of
KHPO
4 1.5 g/L of NaCl, 0.75 g/L of CaCl, 2 7H 2 O, 0.06 g/L of FeSO 4 -7HO, 0.06 g/L of MnSO 4 4H 2 O, 2.16 mg/L of ZnSO 4 2H 2 O, 1.92 mg/L of CuSO4-5H20, 2.16 mg/L of CoC1 2 -6H 2 0, 1.2 mg/L of boric acid, 3.6 mg/L of NaMoO 4 2H20, 6 g/L of yeast extract, 600 mg/L of L-lysine hydrochloride, 600 mg/L of L-methionine, 600 mg/L of DL-a,E-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol and L-glutamic acid crystals were added to 40 g/L. The cells were inoculated in a 1-L jar fermenter containing 300 ml of this medium and cultured at 34 C and pH 4.3 to perform culture for L-glutamic acid production. The culture pH was controlled by introducing ammonia gas into the medium. As the initially added glucose was depleted, 600 g/L of glucose was continuously added. In this medium, only 39 g/L of the added L-glutamic acid was dissolved at pH 4.3 and the remaining 1 g/L was present as crystals.
As a result of the culture for L-glutamic acid production performed for 53 hours as described above, a substantial amount of L-glutamic acid crystals were precipitated in the jar fermenter. Table 2 shows the concentration of L-glutamic acid dissolved in the culture broth, the amount of L-glutamic acid present as crystals at that time and the L-glutamic acid concentration measured by dissolving the crystals in 2 M KOH solution. L-Glutamic acid crystals were collected from the culture by decantation after the culture was left stood. The results showed that the Enterobacter agglomerans AJ13601 strain accumulated Lglutamic acid and precipitated crystals thereof even under the condition that L-glutamic acid crystals were present.
Table 2 Concentration of L-glutamic acid 39 g/L dissolved in culture broth Amount of L-glutamic acid 119 g/L precipitated as crystals Concentration of L-glutamic acid 158 g/L measured by dissolving crystals Amount of L-glutamic acid crystals newly produced by main culture___ Culture of Enterobacter agglomerans AJ13601 strain for L-glutamic acid production (3) The Enterobacter agglomerans AJ13601 strain can grow not only at an acidic pH, but also at a neutral pH. Therefore, it was confirmed as follows that L-glutamic acid crystals could also be precipitated by starting the culture at a neutral pH and allowing production of L-glutamic acid during the culture so that pH of the culture should spontaneously be lowered.
Cells of one plate (8.5 cm in diameter) of the Enterobacter agglomerans AJ13601 strain, cultured on LBG agar medium (10 g/ of L tryptone, 5 g/L of yeast extract, 10 g/L of NaCl, 5 g/L of glucose, 15 g/L of agar) containing mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol at 30 0 C for 14 hours, were inoculated into a 1-L jar fermenter containing 300 ml of medium containing g/L of glucose, 5 g/L of (NH 4
),SO
4 1.5 g/L of MgSO 4 7H 2
O,
6 g/L of KH 2
PO
4 1.5 g/L of NaC1, 0.75 g/L of CaC1,7H0O, 0.06 g/Lof FeSO 4 "7HO, 0.06 g/LofMnSO 4 4H 2 O, 2.16mg/Lof ZnSO 4 1.92 mg/L of CuSO 4 5H20, 2.16 mg/L of CoC1 2 6H20, 1.2 mg/L of boric acid, 3.6 mg/L of Na 2 MoO 4 2HO, 6 g/L of yeast extract, 600 mg/L of L-lysine hydrochloride, 600 mg/L of L-methionine, 600 mg/L of DL-c,E-diaminopimelic acid, 25 mg/L of tetracycline hydrochloride and 25 mg/L of chloramphenicol and the culture was started at 34 C and pH 7.0. The culture pH was controlled by introducing ammonia gas into the medium.
As the initially added glucose was depleted, 600 g/L of glucose was continuously added.
As L-glutamic acid is accumulated, pH lowers spontaneously. The amount of the introduced ammonia gas was adjusted so that pH should be gradually lowered from 7.0 to during the period between 15 hours and 24 hours after the start of the culture, and 24 hours after the start of the culture, pH became 4.5. Afterward, cultivation was continued for 12 hours.
As a result of the culture for L-glutamic acid production conducted for 36 hours as described above, a substantial amount of L-glutamic acid crystals were precipitated in the jar fermenter. Table 3 shows the concentration of L-glutamic acid dissolved in the culture broth, the amount of L-glutamic acid present as crystals at that time and the L-glutamic acid concentration measured by dissolving the crystals in 2 M KOH solution. L-Glutamic acid crystals were collected from the culture by decantation after the culture was left stood.
43 Table 3 Concentration of L-glutamic acid dissolved in culture broth Amount of L-glutamic acid precipitated as crystals g Concentration of L-glutamic acid measured by dissolving crystals
Claims (10)
- 2. The method according to claim 1 wherein said microorganism has at least one of the following characteristics: the microorganism is enhanced in activity of an enzyme that catalyzes a reaction for biosynthesis of L- glutamic acid; and the microorganism is decreased in or deficient activity of an enzyme that catalyzes a reaction branching from a biosynthetic pathway of L-glutamic acid and producing a compound other than L-glutamic acid.
- 3. The method of claim 2, wherein the enzyme that catalyzes the reaction for biosynthesis of L-glutamic acid is at least one selected from citrate synthase, phosphoenolpyruvate carboxylase and glutamate dehydrogenase.
- 4. The method according to any one of claims 1 to 3, wherein the enzyme that catalyzes the reaction branching from the biosynthetic pathway of L-glutamic acid and producing the compound other than L-glutamic acid is a- N \Mclboum\Cases\Paetk3900039999\P3923 1 AU, I\Specis\P39231 AU I Speification 2007-10-18doc I8-Oct-07 ketogluterate dehydrogenase. c( O 5. The method according to any one of claims 1 to 4, wherein the microorganism belongs to the genus 00 5 Enterobacter. ND 6. The method according to claim 5, wherein the microorganism is Enterobacter agglomerans.
- 7. The method according to claim 6, wherein the Smicroorganism is Enterobacter agglomerans (AJ13601) FERM C1 BP-7207.
- 8. The method according to claim 6, wherein the 1i microorganism has a mutation that causes less extracellular secretion of a viscous material compared with a wild strain when cultured in a medium containing a saccharide.
- 9. A method of screening for a microorganism suitable for producing L-glutamic acid by fermentation, with precipitating L-glutamic acid in a liquid medium of pH to 5.0, which comprises inoculating a sample containing microorganisms into an acidic medium containing L-glutamic acid at a saturation concentration and a carbon source, and selecting a strain that can metabolize the carbon source. The method according to claim 9, wherein a strain that can grow in the medium is selected as the strain that can metabolize the carbon source.
- 11. A method for producing L-glutamic acid by fermentation, which comprises starting culturing a microorganism in a liquid medium at a neutral pH and ending said culture at a pH at which L-glutamic acid is precipitated, wherein said microorganism can metabolize a N \Mceboumc\Cases\Pate,\390O-39999\P39231 AU. I\Specis\P3923 .AU I Specification 2007. O-doc 18-Oct-07 46 0 carbon source at a pH of 3.0 to 5.0, in a liquid medium containing L-glutamic acid at a saturation concentration O and the carbon source, and has ability to accumulate L- 00 glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH.
- 12. The method according to claim 11, wherein the culture 0 pH is controlled by introducing ammonia gas into the V 10 medium.
- 13. A microorganism having the accession number FERM BP-
- 7207. 14. A method according to any one of claims 1, 9, or 11, or a microorganism according to claim 13, substantially as herein described with reference to the examples and drawings. 15. Use of a microorganism which can metabolize a carbon source at a pH of 3.0 to 5.0 in a liquid medium containing L-glutamic acid at a saturation concentration and the carbon source, and has the ability to accumulate L- glutamic acid in an amount exceeding the amount corresponding to the saturation concentration in the liquid medium at the pH, for producing L-glutamic acid by fermentation, the method comprising culturing a microorganism in a liquid medium of which pH is adjusted to a pH at which L-glutamic acid is precipitated to produce and accumulate L-glutamic acid and precipitate L- glutamic acid in the medium containing a carbon source, wherein the pH is 3.0 to N.\Mclbure\Cases\Paicnt\.39 .39999\P3923 AU IkSpcis\P3923 AU I Specification 2007-10. 1 doc I8-Oct-07
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005200716A AU2005200716B2 (en) | 1999-08-20 | 2005-02-17 | Method for producing L-glutamic acid by fermentation accompanied by precipitation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11-234806 | 2000-03-21 | ||
JP12-78771 | 2000-03-21 | ||
AU53452/00A AU5345200A (en) | 1999-08-20 | 2000-08-17 | Method for producing L-glutamic acid by fermentation accompanied by precipitation |
AU2005200716A AU2005200716B2 (en) | 1999-08-20 | 2005-02-17 | Method for producing L-glutamic acid by fermentation accompanied by precipitation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU53452/00A Division AU5345200A (en) | 1999-08-20 | 2000-08-17 | Method for producing L-glutamic acid by fermentation accompanied by precipitation |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2005200716A1 AU2005200716A1 (en) | 2005-03-17 |
AU2005200716B2 true AU2005200716B2 (en) | 2008-02-14 |
Family
ID=34397453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005200716A Expired AU2005200716B2 (en) | 1999-08-20 | 2005-02-17 | Method for producing L-glutamic acid by fermentation accompanied by precipitation |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2005200716B2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2122399A (en) * | 1998-03-18 | 1999-09-30 | Ajinomoto Co., Inc. | L-glutamic acid-producing bacterium and method for producing L-glutamic acid |
-
2005
- 2005-02-17 AU AU2005200716A patent/AU2005200716B2/en not_active Expired
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2122399A (en) * | 1998-03-18 | 1999-09-30 | Ajinomoto Co., Inc. | L-glutamic acid-producing bacterium and method for producing L-glutamic acid |
Also Published As
Publication number | Publication date |
---|---|
AU2005200716A1 (en) | 2005-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE42350E1 (en) | Method for producing L-glutamic acid by fermentation accompanied by precipitation | |
US6596517B2 (en) | Method for producing L-glutamic acid | |
USRE41800E1 (en) | Method for producing l-glutamic acid | |
AU782737B2 (en) | Organic nitrogen-containing composition and fertilizer comprising the same | |
US6653110B2 (en) | Method for producing L-glutamic acid | |
AU2005200716B2 (en) | Method for producing L-glutamic acid by fermentation accompanied by precipitation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |